Shots:
- The EC has approved Sarclisa with SoC VRd (bortezomib, lenalidomide, & dexamethasone) to treat ASCT-ineligible NDMM patients, following the CHMP’s positive opinion. Regulatory findings are under review in Japan & China
- Approval was based on a P-III (IMROZ) study assessing Sarclisa + VRd vs VRd, which showed improved PFS of 40% (1EP) with findings reported in Jun 2024
- Additionally, Sanofi is evaluating Sarclisa in various P-II & P-III studies for 6 potential indications across MM treatment, plus SC administration for Sarclisa is also under evaluation
Ref: Sanofi | Image: Sanofi
Related News:- Alloy Therapeutics Partners with Sanofi to Advance Innovative Therapeutics in the CNS Space
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
